Horn T - Search Results

1

Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic.

Killelea A, Johnson J, Dangerfield DT, Beyrer C, McGough M, McIntyre J, Gee RE, Ballreich J, Conti R, Horn T, Pickett J, Sharfstein JM. Killelea A, et al. Among authors: horn t. J Law Med Ethics. 2022;50(S1):8-23. doi: 10.1017/jme.2022.30. J Law Med Ethics. 2022. PMID: 35902089 Free PMC article.

2

Associated Costs Are a Barrier to HIV Preexposure Prophylaxis Access in the United States.

Srikanth K, Killelea A, Strumpf A, Corbin-Gutierrez E, Horn T, McManus KA. Srikanth K, et al. Among authors: horn t. Am J Public Health. 2022 Jun;112(6):834-838. doi: 10.2105/AJPH.2022.306793. Epub 2022 Apr 14. Am J Public Health. 2022. PMID: 35420893 Free PMC article. No abstract available.

3

Insurance coverage and financing landscape for HIV treatment and prevention in the USA.

Kates J, Dawson L, Horn TH, Killelea A, McCann NC, Crowley JS, Walensky RP. Kates J, et al. Lancet. 2021 Mar 20;397(10279):1127-1138. doi: 10.1016/S0140-6736(21)00397-4. Epub 2021 Feb 19. Lancet. 2021. PMID: 33617778 Review.

4

Worsening Disparities in State-Level Uptake of Human Immunodeficiency Virus Preexposure Prophylaxis, 2014-2018.

Powers SD, Rogawski McQuade ET, Killelea A, Horn T, McManus KA. Powers SD, et al. Among authors: horn t. Open Forum Infect Dis. 2021 Jun 4;8(7):ofab293. doi: 10.1093/ofid/ofab293. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34250195 Free PMC article.

5

Economic benefits of the United States' AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities.

McManus KA, Strumpf A, Killelea A, Horn T, Hamp A, Keim-Malpass J. McManus KA, et al. Among authors: horn t. Prev Med Rep. 2022 Aug 29;29:101969. doi: 10.1016/j.pmedr.2022.101969. eCollection 2022 Oct. Prev Med Rep. 2022. PMID: 36161113 Free PMC article.

6

Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model.

Horn T, Sherwood J, Remien RH, Nash D, Auerbach JD; Treatment Action Group and Foundation for Aids Research HIV Prevention Continuum Working Group. Horn T, et al. J Int AIDS Soc. 2016 Nov 17;19(1):21263. doi: 10.7448/IAS.19.1.21263. eCollection 2016. J Int AIDS Soc. 2016. PMID: 27863535 Free PMC article.

7

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Walensky RP, et al. Among authors: horn t. Ann Intern Med. 2020 May 5;172(9):583-590. doi: 10.7326/M19-3478. Epub 2020 Mar 10. Ann Intern Med. 2020. PMID: 32150602 Free PMC article.

8

Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.

Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Walensky RP, et al. Among authors: horn t. Ann Intern Med. 2020 Sep 15;173(6):507-508. doi: 10.7326/L20-0693. Ann Intern Med. 2020. PMID: 32926822 No abstract available.

9

The Epi-TAF for Tenofovir Disoproxil Fumarate?

Walensky RP, Horn TH, Paltiel AD. Walensky RP, et al. Clin Infect Dis. 2016 Apr 1;62(7):915-8. doi: 10.1093/cid/civ1000. Epub 2015 Dec 9. Clin Infect Dis. 2016. PMID: 26658300

10

HIV Antiretroviral Therapy Costs in the United States, 2012-2018.

McCann NC, Horn TH, Hyle EP, Walensky RP. McCann NC, et al. JAMA Intern Med. 2020 Apr 1;180(4):601-603. doi: 10.1001/jamainternmed.2019.7108. JAMA Intern Med. 2020. PMID: 32011622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

774 results

Search Page